shutterstock_1147238582_testing
Testing / Shutterstock.com
31 October 2019Big PharmaSaman Javed

Roche enters $200m hep B treatment collaboration

Roche has entered into a $200 million agreement to licence Dicerna’s GalXC RNAi platform technology to develop novel therapies for the treatment of chronic hepatitis B.

In an announcement earlier today, October 31, Dicerna said both parties had agreed to collaborate on the development of therapies targeting multiple human and viral genes implicated in hep B infection.

Dicerna will receive $200 million in an initial upfront payment and may be eligible to receive up to an additional $1.47 billion over time for specified development and commercial milestones.

Additionally, it may be eligible to receive additional royalties on any products made in collaboration with Roche.

Douglas Fambrough, president and CEO of Dicerna said the collaboration is an opportunity to “target and silence specific genes that contribute to chronic hepatitis B virus infection”.

“With its deep expertise in hep B and established global infrastructure, Roche is ideally suited to help us pursue a cure for chronic hep B infection, and address this serious global threat to public health,” Fambrough added.

John Young, global head of infectious diseases at Roche early research & development said: “This partnership builds upon our existing portfolio and internal expertise and positions us well to develop a best-in-disease therapy to cure chronic hep B infection."

Did you enjoy reading this story?  Sign up to our free daily newsletters and get stories sent like this straight to your inbox.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
23 July 2019   The English High Court has ruled that a patent owned by Roche should be revoked on grounds of insufficiency.
Big Pharma
7 November 2019   The US Court of Appeals for the Second Circuit has dismissed a Russian pharmaceutical company’s antitrust claims against Roche.
Americas
19 November 2019   Switzerland-based Roche has agreed to acquire Promedior and its portfolio of molecules for serious fibrotic diseases.

More on this story

Big Pharma
23 July 2019   The English High Court has ruled that a patent owned by Roche should be revoked on grounds of insufficiency.
Big Pharma
7 November 2019   The US Court of Appeals for the Second Circuit has dismissed a Russian pharmaceutical company’s antitrust claims against Roche.
Americas
19 November 2019   Switzerland-based Roche has agreed to acquire Promedior and its portfolio of molecules for serious fibrotic diseases.

More on this story

Big Pharma
23 July 2019   The English High Court has ruled that a patent owned by Roche should be revoked on grounds of insufficiency.
Big Pharma
7 November 2019   The US Court of Appeals for the Second Circuit has dismissed a Russian pharmaceutical company’s antitrust claims against Roche.
Americas
19 November 2019   Switzerland-based Roche has agreed to acquire Promedior and its portfolio of molecules for serious fibrotic diseases.